Assessing The Value Of Your Patents
Terry LudlowChipworks Michael SpenceChipworks What are the factors that influence patent value? They fall into three areas: legal, technical, and market.
Standing Of Licensees To Sue For IP Infringement In Australia
Peter HallettWatermark IP Lawyers Sean McGuireWatermark IP Lawyers The Full Court of the Federal Court of Australia has handed down an important decision for those involved in patent licensing in Australia: Bristol-Myers Squibb Company v Apotex Pty Ltd [2015] FCAFC 2.
Downgrade To “Neutral”: A Diminishing Role Of The Georgia-Pacific Factors In Reasonable Royalty Analyses
Ryan SullivanIntensity Corporation DeForest McDuffIntensity Corporation Justin SkinnerIntensity Corporation More than 80% of damages awards in patent liti-gation include reasonable royalties. In these litigations, reasonable royalty analyses by economic experts often involve a linear and monotonous march through the fifteen economic factors listed in Georgia-Pacific v. United States Plywood (S.D.N.Y. 1970), commonly referred to as the Georgia-Pacific […]
Computer Assisted Generation Of IP Transaction Documents
William BirdIPLodge bvba When advising a company about drafting IP trans-actions such as IP licensing agreements or assign-ments, one would normally recommend a qualified attorney—preferably (of course) an active and experienced member of LES. However, we know that computer software is being used to generate IP transaction documents and that raises the question of how […]
IP Licensing In A 3D Printed World
John HornickFinnegan At first blush, a world where parts and products are 3D printed at home or on the factory floor may seem like a potential IP licensing bonanza. In reality, 3D printing may create some IP licensing opportunities and destroy others.
Recent U.S. Court Decisions And Developments Affecting Licensing
John C. PaulFinnegan, Henderson, Farabow, Garrett & Dunner, LLP D. Brian KacedonFinnegan, Henderson, Farabow, Garrett & Dunner, LLP In the 1970s, the Supreme Court identified a loophole in the patent statute, whereby one could manufacture in the United States components of an infringing product and export those components for assembly and use of the infringing […]
Risk And Return: Understanding The Cost Of Capital For Intellectual Property Part 1 of 2
Glenn PerdueKraft Analytics LLC Human beings are hardwired to assess risk and return. Whether driving faster to avoid being late for a meeting or demanding more equity to invest in a deal, we constantly consider the tradeoffs between risk and what we stand to gain by accepting that risk.
Collaborating For Growth: The Novel Cross-Licensing Model That WoodWelding SA Used To Break Into New Markets Globally
Gerhard PlasonigWoodWelding SA Pernilla (Kvist) PlasonigWoodWelding SA Martina SerafiniWoodWelding SA Evan LaBuzettaWritling Language Consultants, Ltd. When Swiss researchers invented a method for using ultrasonic energy to infuse thermoplastics into wood and other porous materials, they found themselves in a challenging business position. The technology created a near-instant, very stable bond that could be used to […]
What’s Trending In IP Deals?
David R. JarczykktMINE John WioraktMINE Danielle LambertktMINE On October 6, 2014, David R. Jarczyk, David Drews, and Dwight Olson presented a study of trends in the pharmaceutical, semiconductor, chemical, telecommunication and consumer product industries at the LES USA & Canada Annual Meeting entitled, LESI IP Valuation Committee Study on Royalty Rates & Deal Structures. This […]
The Scoop From Europe: European Commission Decisions Finally Published In Lundbeck And Fentanyl Pay-For-Delay Cases
Patricia CappuynsCappuyns Intellectual Property Law As a result of the pharma sector inquiry opened in January 2008, the European Commission issued three decisions for “pay-for-delay” competition law violations in the pharmaceutical industry: the Lundbeck decision re Citalopram in June 2013, the Fentanyl decision in December 2013 and the Servier decision re Perindopril in July 2014. An investigation of Cephalon and Teva […]
